On September 30, GENSCRIPT BIO rose 3.53% in regular trading, trading at 44.1 HKD/share, with turnover of approximately 140 million HKD.

On the news front, the latest HKEX disclosure of interests filings revealed that two international institutional investors successively crossed the 5% disclosure threshold through active secondary market purchases. FMR LLC acquired 6.846 million shares on September 24 at an average price of approximately 40.25 HKD per share, committing roughly 276 million HKD. Its long position rose from 4.96% to 5.26%, totaling approximately 120 million shares. Separately, 483A Bay Street Holdings and related entities purchased approximately 2.795 million shares on September 23 at an average price of 41.78 HKD, raising their combined long position from 4.98% to 5.1%, involving approximately 117 million HKD.

The back-to-back threshold crossings by two major institutions represent a notable vote of confidence following the stock's recent rally driven by its Lilly TuneLab collaboration and strong AI-driven drug discovery momentum. The company previously projected triple-digit percentage growth in AI-driven protein orders for the second half and beyond, supported by a recent 2.33 billion HKD share placement earmarked largely for AIDD platform capacity expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)